Clinical trial · Observational
Stop Ovarian Cancer Young; Effect of the Opportunistic Salpingectomy on Age of Menopause
NCT04757922CI-TRIAL-00073326STOPOVCAyoungenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to evaluate the long-term safety of on the onset of menopause.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Menopause | — | UNRESOLVED | — |
| Salpingectomy | — | UNRESOLVED | — |
| Tubal Ligation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Opportunistic salpingectomy / bilateral salpingectomy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Intervention: bilateral salpingectomy
- description
- Premenopausal women between 30 and 45 years of age, who will undergo sterilization through Opportunistic Salpingectomy will be asked to participate in the STOPOVCAyoung study.
- interventionNames
- Procedure: Opportunistic salpingectomy / bilateral salpingectomy
- label
- Control: tubal ligation or no sterilization
- description
- The control group will consists of women who chose for sterilization by clips/tubal ligation supplemented by friend/acquaintances, around the same age, who are not planning to undergo sterilization.
Primary outcomes (1)
- measure
- Menopausal age
- timeFrame
- At end of follow-up (follow up ends at age of menopause with a maximum follow-up time of 15 years)
- description
- The age of reaching natural menopause (e.g. last menstruation \> 1 year ago )
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: Intervention group * Undergoing an Opportunistic Salpingectomy as sterilization method * Premenopausal status at enrolment * Age between 30 and 45 years * Will have residual ovarian tissue after surgery * Able to understand the written or spoken Dutch language * Gives consent for participating in surveys Control group * Premenopausal status at enrolment * Either sterilization by tubal ligation or no sterilization at all * Age between 35 and 45 years * Able to understand the written or spoken Dutch language * Gives consent for participating in surveys Exclusion Criteria: * Postmenopausal status at enrolment * Under the age of 35 or above 45 * Previous salpingectomy of oophorectomy * Previous hysterectomy * Women with abnormal karyotype (such as Turner Syndrome and Fragile X syndrome) * Underwent chemotherapy or radiation * Unable to understand the written or spoken Dutch language
References
Publications (7)
- BACKGROUNDPiek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451-6. doi: 10.1002/path.1000. PMID 11745677
- BACKGROUNDReade CJ, McVey RM, Tone AA, Finlayson SJ, McAlpine JN, Fung-Kee-Fung M, Ferguson SE. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift. J Obstet Gynaecol Can. 2014 Feb;36(2):133-140. doi: 10.1016/S1701-2163(15)30659-9. PMID 24518912
- BACKGROUNDFalconer H, Yin L, Gronberg H, Altman D. Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst. 2015 Jan 27;107(2):dju410. doi: 10.1093/jnci/dju410. Print 2015 Feb. PMID 25628372
- BACKGROUNDvan Lieshout LAM, Steenbeek MP, De Hullu JA, Vos MC, Houterman S, Wilkinson J, Piek JM. Hysterectomy with opportunistic salpingectomy versus hysterectomy alone. Cochrane Database Syst Rev. 2019 Aug 28;8(8):CD012858. doi: 10.1002/14651858.CD012858.pub2. PMID 31456223
- BACKGROUNDHanley GE, Kwon JS, Finlayson SJ, Huntsman DG, Miller D, McAlpine JN. Extending the safety evidence for opportunistic salpingectomy in prevention of ovarian cancer: a cohort study from British Columbia, Canada. Am J Obstet Gynecol. 2018 Aug;219(2):172.e1-172.e8. doi: 10.1016/j.ajog.2018.05.019. Epub 2018 May 28. PMID 29852159
- BACKGROUNDMcAlpine JN, Tone AA, Hanley GE. Opportunistic Salpingectomy: We Chose to Act, Not Wait. J Obstet Gynaecol Can. 2016 May;38(5):425-7. doi: 10.1016/j.jogc.2016.04.084. Epub 2016 May 6. No abstract available. PMID 27261215
- DERIVEDGelderblom ME, IntHout J, Hermens RPMG, Coppus SFPJ, Ebisch I, van Ginkel AA, van de Laar R, de Lange N, Maassen M, Pijlman B, Smedts HPM, Vos MC, Beerendonk CCM, de Hullu JA, Piek JMJ. STop OVarian CAncer (STOPOVCA) young: Protocol for a multicenter follow-up study to determine the long-term effects of opportunistic salpingectomy on age at menopause. Maturitas. 2022 May;159:62-68. doi: 10.1016/j.maturitas.2022.01.006. Epub 2022 Jan 15.